tradingkey.logo
tradingkey.logo
Pesquisar

BioLife Solutions Inc

BLFS
Adicionar à lista de desejos
28.110USD
-0.380-1.33%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
1.37BValor de mercado
PerdaP/L TTM

Mais detalhes de BioLife Solutions Inc Empresa

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Informações de BioLife Solutions Inc

Código da empresaBLFS
Nome da EmpresaBioLife Solutions Inc
Data de listagemNov 22, 1989
CEODe Greef (Roderick)
Número de funcionários159
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 22
EndereçoSuite 310
CidadeBOTHELL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal98021
Telefone14254011400
Sitehttps://www.biolifesolutions.com/
Código da empresaBLFS
Data de listagemNov 22, 1989
CEODe Greef (Roderick)

Executivos da empresa BioLife Solutions Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
292.78K
-0.41%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
132.07K
-1.49%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
66.03K
-154.97%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
65.47K
-1.76%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
47.83K
-0.88%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
44.99K
-2.88%
Ms. Catherine (Cathy) Coste, CPA
Ms. Catherine (Cathy) Coste, CPA
Independent Director
Independent Director
5.70K
-143.31%
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Amy Duross
Ms. Amy Duross
Lead Independent Director
Lead Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
292.78K
-0.41%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
132.07K
-1.49%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
66.03K
-154.97%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
65.47K
-1.76%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
47.83K
-0.88%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
44.99K
-2.88%

Perguntas frequentes

Quem são os cinco principais acionistas de BioLife Solutions Inc?

Os cinco principais acionistas de BioLife Solutions Inc são: Dr. Aby J. Mathew, Ph.D.

Quantas instituições possuem ações da BioLife Solutions Inc (BLFS)?

Em 2026Q1, 430 instituições possuíam ações da BioLife Solutions Inc, com valor de mercado aproximado de 51.34M, representando 105.07% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1261408.00.